Trump's tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks
Leerink Partners analyst David Risinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Leerink
since
auto-detected in 32 stories
32 days ago
Trump's tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks
Leerink Partners analyst David Risinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
88 days ago
Leerink upgrades this beaten-down biotech stock, says investors should buy the dip
Analyst David Risinger upgraded shares to outperform. He also raised his price target to $834 from $762.
page 1 of 1